Product: VeriStrat
-
Serum Proteomic Classification in Refractory Non-Small-Cell Lung Cancer Treated with Erlotinib +/- Pazopanib in a Randomized Placebo-Controlled Phase II Study
-
Prognostic and Predictive Role of the VeriStrat Plasma Test in Patients with Advanced Non–Small-Cell Lung Cancer Treated with Erlotinib or Placebo in the NCIC Clinical Trials Group BR.21 Trial
-
VeriStrat has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib
-
A plasma proteomic signature predicts outcomes in a Phase 3 study of gemcitabine (G) + cisplatin (C) ± sorafenib in first line stage IIIB or IV non-small cell lung cancer (NSCLC)
-
Changes in Plasma Mass-Spectral Profile in Course of Treatment of Non-small Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
-
Evaluation of VeriStrat Signature in Advanced Bronchioloalveolar Carcinoma (BAC): A Pooled Analysis of IFCT-0401 and 0504 Trials
-
Pre-treatment sera from NSCLC patients with different outcomes on EGFR-TKI therapy differentially affect sensitivity of lung cancer cell lines to EGFR-TKIs
-
The proteomic classifier VeriStrat identifies advanced non-small cell lung cancer (NSCLC) patients gaining clinical benefit from treatment with first line sorafenib and erlotinib
-
VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab
-
Detection of Tumor Epidermal Growth Factor Receptor Pathway Dependence by Serum Mass Spectrometry in Cancer Patients